FN2 Earnings Intelligence
Roivant Sciences Ltd. ratios
Roivant Sciences Ltd. (ROIV) Ratios (annual) derived from persisted SEC financial facts.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 3/31/2022 | 3/31/2023 | 3/31/2024 | 3/31/2025 | 3/31/2026 | 3/31/2027 est. | 3/31/2028 est. |
|---|---|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - | - | - |
| - Cash | $2,060.4 | $1,676.8 | $6,535.7 | $2,715.4 | $1,419.2 | - | - |
| + Debt | - | - | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - | - | - |
| Revenue | $55.3 | $61.3 | $124.8 | $29.1 | $8.3 | $121 | $581.2 |
| % Growth | - | 10.8% | 103.6% | -76.7% | -71.6% | 1,364.5% | 380.4% |
| Gross Profit | - | $354.6 | $376.6 | $461.5 | $668.8 | - | - |
| % Margin | - | 578.6% | 301.8% | 1,588.5% | 8,097.4% | - | - |
| EBITDA | - | -$1,156.5 | $4,264.1 | -$989.2 | -$511.7 | - | - |
| % Margin | - | -1,887.2% | 3,416.8% | -3,404.9% | -6,195.2% | - | - |
| Net Income | -$845.3 | -$1,009 | $4,348.9 | -$172 | -$299.8 | - | - |
| % Margin | -1,528.9% | -1,646.6% | 3,484.9% | -592.0% | -3,629.2% | - | - |
| Diluted EPS | - | -$1.42 | $5.23 | -$0.24 | -$0.54 | -$1.23 | -$1.18 |
| % Growth | - | - | 468.3% | -104.6% | -125.0% | -128.7% | 4.2% |
| Operating Cash Flow | -$677.7 | -$843.4 | -$765.3 | -$839.5 | -$750.3 | - | - |
| CapEx | $17.4 | $12.7 | $1.4 | $4.6 | $8.2 | - | - |
| Free Cash Flow | -$695.2 | -$856.1 | -$766.6 | -$844 | -$758.6 | - | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 3/31/2022 | 3/31/2023 | 3/31/2024 | 3/31/2025 | 3/31/2026 | 3/31/2027 est. | 3/31/2028 est. |
|---|---|---|---|---|---|---|---|
| Revenue | $55.3 | $61.3 | $124.8 | $29.1 | $8.3 | $121 | $581.2 |
| Gross Profit | - | $354.6 | $376.6 | $461.5 | $668.8 | - | - |
| EBITDA | - | -$1,156.5 | $4,264.1 | -$989.2 | -$511.7 | - | - |
| Net Income | -$845.3 | -$1,009 | $4,348.9 | -$172 | -$299.8 | - | - |
| Diluted EPS | - | -$1.42 | $5.23 | -$0.24 | -$0.54 | -$1.23 | -$1.18 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 3/31/2022 | 3/31/2023 | 3/31/2024 | 3/31/2025 | 3/31/2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | $2,060.4 | $1,676.8 | $6,535.7 | $2,715.4 | $1,419.2 |
| Short-term Debt | - | - | - | - | - |
| Long-term Debt | $210 | $375.5 | $430.6 | - | - |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 3/31/2022 | 3/31/2023 | 3/31/2024 | 3/31/2025 | 3/31/2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$677.7 | -$843.4 | -$765.3 | -$839.5 | -$750.3 |
| Capital Expenditure | $17.4 | $12.7 | $1.4 | $4.6 | $8.2 |
| Free Cash Flow | -$695.2 | -$856.1 | -$766.6 | -$844 | -$758.6 |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 3/31/2022 | 3/31/2023 | 3/31/2024 | 3/31/2025 | 3/31/2026 |
|---|---|---|---|---|---|
| Revenue Growth | - | 10.8% | 103.6% | -76.7% | -71.6% |
| Gross Margin | - | 578.6% | 301.8% | 1,588.5% | 8,097.4% |
| EBITDA Margin | - | -1,887.2% | 3,416.8% | -3,404.9% | -6,195.2% |
| Net Margin | -1,528.9% | -1,646.6% | 3,484.9% | -592.0% | -3,629.2% |
| FCF Margin | -1,257.4% | -1,397.0% | -614.3% | -2,905.2% | -9,183.5% |
| Diluted EPS Growth | - | - | 468.3% | -104.6% | -125.0% |
Get the ROIV recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.